UK regulator narrows medical device rules for AI scribes

The UK’s Medicines and Healthcare products Regulatory Agency published guidance on 29 July 2026 clarifying when ambient voice technology-enabled products, or AVTs, fall under UK medical device rules. AVTs are AI-powered tools that capture spoken words and convert them into text or other outputs, including consultation transcripts, summaries, referral letters and other clinical correspondence.

The guidance states that summarization alone does not make an AVT a medical device in Great Britain. The MHRA says an AVT must have an intended purpose that meets the medical device definition under the Medical Devices Regulations 2002, including use for diagnosis, prevention, monitoring, treatment or alleviation of disease. AVTs intended only for transcription, clinical conversation summaries, draft letters, structured documentation for clinician review or suggested clinical codes for review are not regulated as medical devices.

The position reverses confusion created by NHS England guidance in April 2025 and a later priority notification stating that ambient scribing software performing summarization in healthcare must be regulated as at least a Class I medical device. Products move into medical device territory when they offer generated insights such as suggested diagnoses, follow-up or treatment options, claim to guide diagnosis and treatment planning, or autonomously order follow-up tests without clinician review.

NHS England has updated its guidance to point to the MHRA position, but procurement practice remains unsettled because it may still request CE/UKCA evidence for AVTs used within the NHS.